323 related articles for article (PubMed ID: 37928419)
1. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study.
Liu F; Yin G; Xue S; Rehman FU; Liao D; Pan Y
J Cancer; 2023; 14(17):3275-3284. PubMed ID: 37928419
[No Abstract] [Full Text] [Related]
2. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database.
Ma P; Tian H; Shi Q; Liu R; Zhang Y; Qi X; Chen Y
Expert Opin Drug Saf; 2023; 22(8):685-696. PubMed ID: 37068935
[TBL] [Abstract][Full Text] [Related]
3. Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study.
Guo Z; Ding Y; Wang M; Liu J; Zhai Q; Du Q
J Clin Pharm Ther; 2022 Nov; 47(11):1837-1844. PubMed ID: 36200429
[TBL] [Abstract][Full Text] [Related]
4. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System.
Cecco S; Puligheddu S; Fusaroli M; Gerratana L; Yan M; Zamagni C; De Ponti F; Raschi E
Target Oncol; 2024 May; 19(3):435-445. PubMed ID: 38696126
[TBL] [Abstract][Full Text] [Related]
5. Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance.
Morgovan C; Dobrea CM; Butuca A; Arseniu AM; Frum A; Rus LL; Chis AA; Juncan AM; Gligor FG; Georgescu C; Ghibu S; Vonica-Tincu AL
Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790915
[TBL] [Abstract][Full Text] [Related]
6. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
Perez EA; Dang C; Lee C; Singh J; Wang K; Layton JB; Gilsenan A; Hackshaw MD; Cortes J
Breast Cancer Res Treat; 2022 Jul; 194(1):1-11. PubMed ID: 35587323
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
[TBL] [Abstract][Full Text] [Related]
8. Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS).
Bao Y; Chen J; Duan L; Wang F; Lai H; Mo Z; Zhu W
Front Pharmacol; 2024; 15():1288362. PubMed ID: 38327983
[No Abstract] [Full Text] [Related]
9. Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
Waliany S; Caswell-Jin J; Riaz F; Myall N; Zhu H; Witteles RM; Neal JW
JACC CardioOncol; 2023 Feb; 5(1):85-98. PubMed ID: 36875913
[TBL] [Abstract][Full Text] [Related]
10. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
Tang L; Sun C; Liu W; Wu H; Ding C
Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285
[No Abstract] [Full Text] [Related]
11. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
[No Abstract] [Full Text] [Related]
13. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting.
Hu S; Wu Y; Luan J; Wang S; Fan G
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17933-17942. PubMed ID: 37964082
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis.
Zhu Y; Liu K; Wang M; Wang K; Zhu H
Breast; 2022 Dec; 66():191-198. PubMed ID: 36327624
[TBL] [Abstract][Full Text] [Related]
17. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K
Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938
[TBL] [Abstract][Full Text] [Related]
18. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.
Ciruelos E; García-Sáenz JÁ; Gavilá J; Martín M; Rodríguez CA; Rodríguez-Lescure Á
Clin Transl Oncol; 2024 Feb; ():. PubMed ID: 38336982
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database.
Long P; Li S; Pan L; Wang Y; Chen W; Wang X
Front Pharmacol; 2024; 15():1378010. PubMed ID: 38766629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
